[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1985

Griseofulvin-Oral Contraceptive Interaction

Author Affiliations

1416 59th St W Bradenton, FL 33529

Arch Dermatol. 1985;121(11):1381. doi:10.1001/archderm.1985.01660110029007

To the Editor.—  An article entitled "Interaction Between Oral Contraceptives and Griseofulvin" appeared in the British Medical Journal in 1984.1 This article suggested that systemic administration of griseofulvin in 22 women may have increased the metabolism, or, at any rate, decreased the effectiveness of the estrogen that was being used as part of a contraceptive pill. As a result, 15 patients experienced transient intermenstrual bleeding and five had amenorrhea; unintended pregnancies were reported in two other patients. In four women, two with intermenstrual bleeding and two with amenorrhea, a second exposure to griseofulvin resulted in recurrence of the original reaction. The authors did not state the formulation of griseofulvin (ie, ultramicrofine, microcrystalline, and so on) employed.Of the two women with unintended pregnancy, one had used high-dose oral contraception for 15 months and had been receiving 500 mg/day of griseofulvin for 2½ months. She also received co-trimoxazole for one